Drug Profile
Anti-CD3-anti-EGFR monoclonal antibody
Alternative Names: Bispecific monoclonal antibody M26.1; Bispecific monoclonal antibody OKT3-EGFRLatest Information Update: 07 Aug 1998
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; Epidermal growth factor receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Aug 1998 Profile reviewed
- 07 Aug 1998 No-Development-Reported for Cancer in Germany (Unknown route)
- 07 Aug 1998 No-Development-Reported for Cancer in Italy (Unknown route)